erlotinib hydrochloride has been researched along with dapsone in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (dapsone) | Trials (dapsone) | Recent Studies (post-2010) (dapsone) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5,116 | 379 | 862 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | dapsone (IC50) |
|---|---|---|---|
| Myeloperoxidase | Homo sapiens (human) | 0.42 | |
| Dihydrofolate reductase | Pneumocystis carinii | 1.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Addeo, R; Alaia, C; Boccellino, M; Caraglia, M; Grimaldi, A; Kast, RE; Nicoletti, GF; Quagliuolo, L | 1 |
| Consuegra, G; Fernandez-Penas, P; Hui, R; Liu, RC; Zhao, CY | 1 |
1 review(s) available for erlotinib hydrochloride and dapsone
| Article | Year |
|---|---|
The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.
Topics: Antineoplastic Agents; Dapsone; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Interleukin-8 | 2016 |
1 other study(ies) available for erlotinib hydrochloride and dapsone
| Article | Year |
|---|---|
Epidermal growth factor receptor inhibitor-induced papulopustular eruption successfully treated with low-dose oral dapsone.
Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Dapsone; Dose-Response Relationship, Drug; Drug Eruptions; Erlotinib Hydrochloride; Facial Dermatoses; Female; Follow-Up Studies; Humans; Lung Neoplasms; Middle Aged; Scalp Dermatoses; Treatment Outcome | 2018 |